|Videos|June 26, 2020

Was Arizona Prepared for COVID-19?

A look at how the state became a belated hotspot, and what may help reduce future infection growth.

This time last week, the state of Arizona had reported 3246 new cases of coronavirus 2019 (COVID-19)—then a new daily record. At this time one week later, the state is still reporting 3000-plus daily new cases, as the virus’ greatest rises have moved southwest nationally.

Though very recent elements at play for Arizona spelled the rise in cases it is currently seeing, there remains questions as to whether this state—and many other new hotspots—were prepared for a COVID-19 spread.

It was—at least in terms of preparing personal protective equipment (PPE), hospital staffing, and testing availability. Preparedness wasn’t reflected in much else, Saskia Popescu, PhD, MPH, MA, CIC, told Contagion®.

“There’s only so much you can do if open the floodgates to exposures through community-based reopening efforts that were too soon and too fast,” Popescu said.

In the latter half of an interview with Contagion, Popescu, the Phoenix, AZ-based epidemiologist and frequent site contributor, explained how recent efforts to enforce public mask-wearing and rebolstered social distancing felt “contraindicated” in her state.

She also discussed lessons legislators may have hopefully learned from this spike in new cases: how major decisions can influence public perception of this pandemic.

“When you do reopen, it almost gives the impression that things are fine, that there’s no COVID in the community,” she explained. “And unfortunately, I think that communication was lacking.”


Related to this article

Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Measles Update: October 16, 2026
The latest CDC numbers show an 8.1% increase in measles cases from week-to-week, bringing the 2026 US total to 4410 confirmed cases. A CDC disease detective is going to Pennsylvania to aid in the state's massive outbreak, and the agency reports on a rare measles complication that is uniformly fatal.